LEO LUZNIK to Mice
This is a "connection" page, showing publications LEO LUZNIK has written about Mice.
Connection Strength
0.377
-
Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen. Transplantation. 2016 Dec; 100(12):e140-e146.
Score: 0.032
-
Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014 Sep 25; 124(13):2131-41.
Score: 0.027
-
High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010 Nov; 17(6):493-9.
Score: 0.021
-
High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010 Jul; 47(1-3):65-77.
Score: 0.020
-
STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol. 2010 Jan 15; 184(2):764-74.
Score: 0.020
-
Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010 Jan; 59(1):137-48.
Score: 0.019
-
Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity. Transplantation. 2007 Mar 15; 83(5):631-40.
Score: 0.016
-
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood. 2007 May 15; 109(10):4564-74.
Score: 0.016
-
Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol. 2006 Oct 01; 177(7):4414-25.
Score: 0.016
-
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024 Apr; 5(4):601-624.
Score: 0.013
-
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood. 2003 Feb 15; 101(4):1645-52.
Score: 0.012
-
Efflux capacity and aldehyde dehydrogenase both contribute to CD8+ T-cell resistance to posttransplant cyclophosphamide. Blood Adv. 2022 09 13; 6(17):4994-5008.
Score: 0.012
-
Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation. J Clin Invest. 2022 07 01; 132(13).
Score: 0.012
-
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022 05 12; 139(19):2983-2997.
Score: 0.012
-
Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002; 8(3):131-8.
Score: 0.011
-
Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 01; 98(12):3456-64.
Score: 0.011
-
Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood. 2020 01 02; 135(1):28-40.
Score: 0.010
-
Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease. Am J Transplant. 2019 06; 19(6):1820-1830.
Score: 0.009
-
Short telomere syndromes cause a primary T cell immunodeficiency. J Clin Invest. 2018 12 03; 128(12):5222-5234.
Score: 0.009
-
Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2019 01 03; 133(1):94-99.
Score: 0.009
-
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-? production. Blood. 2017 05 04; 129(18):2570-2580.
Score: 0.008
-
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Feb; 23(2):211-234.
Score: 0.008
-
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 04 28; 127(17):2144-54.
Score: 0.008
-
Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016 Apr; 22(4):594-604.
Score: 0.008
-
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood. 2016 Jan 21; 127(3):352-9.
Score: 0.007
-
Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94.
Score: 0.007
-
Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98.
Score: 0.007
-
Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model. Bone Marrow Transplant. 2013 Oct; 48(10):1335-41.
Score: 0.006
-
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012 Feb 09; 119(6):1570-80.
Score: 0.006
-
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant. 2008 May; 14(5):499-509.
Score: 0.004